There are currently 2700 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
NCT05462145
Recruiting
This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/03/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037
Recruiting
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
Register for Updates
A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
NCT05955261
Recruiting
This is a phase 2 study to test the hypothesis that venetoclax in combination with standard chemotherapy will be tolerable and active in pediatric patients with newly diagnosed acute myeloid leukemia (AML). Primary Objectives: * Establish the tolerability adding venetoclax to standard chemotherapy in pediatric patients with AML * Estimate the proportion of patients who become minimal residual disease (MRD) negative by flow cytometry after one course of venetoclax-based induction therapy Secon... Read More
Gender:
ALL
Ages:
Between 29 days and 21 years
Trial Updated:
07/03/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia
Register for Updates
GpCRC Pediatric Gastroparesis Registry 2
NCT05981300
Recruiting
The objective of the Pediatric Gastroparesis Registry 2 is to create a national prospective registry of children, adolescents, and young adults with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying).
Gender:
ALL
Ages:
Between 8 years and 25 years
Trial Updated:
07/03/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Gastroparesis, Gastroparesis-like Syndrome
Register for Updates
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
NCT06042257
Recruiting
The purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12 years of age with Down syndrome (DS) after 8 weeks of treatment.
Gender:
ALL
Ages:
Between 6 years and 12 years
Trial Updated:
07/03/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
Register for Updates
Chiropractic Care for Episodic Migraine
NCT06229834
Recruiting
Migraine, a chronic intermittent headache disorder, ranks in the top five causes of years lived with disability. One promising non-pharmacologic and integrative treatment for migraine may be chiropractic care due to the co-occurrence of migraine and musculoskeletal complaints. The goal of this application is to perform a pilot study of chiropractic care for episodic migraine to help inform the design of a future, full-scale pragmatic effectiveness trial.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/03/2025
Locations: Osher Center for Integrative Health, Mass General Brigham, Boston, Massachusetts
Conditions: Episodic Migraine
Register for Updates
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
NCT06284486
Recruiting
To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/03/2025
Locations: Dana-Farber Cancer Center, Boston, Massachusetts
Conditions: Acute Myeloid Leukemia
Register for Updates
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
NCT06399302
Recruiting
This project aims to collect detailed clinical data, blood samples, and patient-reported outcomes from 2,600 lung transplant candidates, donors, and recipients at Lung Transplant Centers. The goal is to create a robust resource for various research objectives, including studying the impact of variations in donor and medical practices on clinical outcomes. The project also seeks to identify serum biomarkers associated with or predictive of specific post-transplant complications and conditions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Brigham and Womens Hospital, Boston, Massachusetts
Conditions: Lung Transplant; Complications, Lung Transplant; Infection or Inflammation, Lung Transplant Rejection, Lung Transplant Failure
Register for Updates
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934
Recruiting
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/03/2025
Locations: Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286, Boston, Massachusetts
Conditions: Dermatitis Atopic
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
NCT06706674
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/03/2025
Locations: Clinical Site, Boston, Massachusetts
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06798012
Recruiting
CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG). TAK-411 is a special type of immune globu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Register for Updates
CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation
NCT06708299
Recruiting
Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 14 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients who discontinue therapy with an IL-1 blocke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Recurrent Pericarditis
Register for Updates